v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment The following table summarizes reportable segment revenues, expenses, and profit and provides a reconciliation of total
reportable segment Adjusted EBITDA to Net income (loss) for the periods indicated:
Three Months Ended March 31,
2026
2025
Academia & Government
Revenues
$295.0
$302.7
People-related costs
(85.3)
(86.2)
Royalties and other product costs
(45.1)
(55.1)
Technology costs
(21.0)
(19.6)
Outside service costs
(7.3)
(9.1)
Other costs
(9.7)
(8.9)
A&G Adjusted EBITDA
$126.6
$123.8
Intellectual Property
Revenues
$197.2
$192.7
People-related costs
(73.2)
(72.7)
Royalties and other product costs
(15.9)
(18.0)
Technology costs
(12.8)
(12.3)
Outside service costs
(4.2)
(5.7)
Other costs
(5.7)
(5.2)
IP Adjusted EBITDA
$85.4
$78.8
Life Sciences & Healthcare
Revenues
$93.3
$98.3
People-related costs
(43.7)
(46.8)
Royalties and other product costs
(8.8)
(8.8)
Technology costs
(6.6)
(7.0)
Outside service costs
(2.0)
(2.6)
Other costs
(3.0)
(2.5)
LS&H Adjusted EBITDA
$29.2
$30.6
Total Reportable Segments
Revenues
$585.5
$593.7
People-related costs
(202.2)
(205.7)
Royalties and other product costs
(69.8)
(81.9)
Technology costs
(40.4)
(38.9)
Outside service costs
(13.5)
(17.4)
Other costs
(18.4)
(16.6)
Total Reportable Segments Adjusted EBITDA
$241.2
$233.2
Benefit (provision) for income taxes
(11.4)
(18.8)
Depreciation and amortization
(184.0)
(185.4)
Interest expense, net
(59.0)
(64.3)
Share-based compensation expense
(14.6)
(11.1)
Restructuring costs
(12.0)
(24.7)
Transaction related costs
(8.2)
(6.3)
Other(1)
7.8
(26.5)
Net income (loss)
$(40.2)
$(103.9)
(1)Includes the net impact of foreign exchange gains and losses related to the remeasurement of balances and other items that do not reflect our ongoing
operating performance.